AUDENTES THERAPEUTICS INC's ticker is BOLD and the CUSIP is 05070R104. A total of 193 filers reported holding AUDENTES THERAPEUTICS INC in Q4 2019. The put-call ratio across all filers is 5.36 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $38,243,000 | -54.0% | 639,095 | -78.4% | 0.92% | -67.1% |
| Q3 2019 | $83,221,000 | -26.0% | 2,962,655 | -0.3% | 2.78% | -12.5% |
| Q2 2019 | $112,526,000 | +5.4% | 2,972,167 | +8.7% | 3.18% | +2.0% |
| Q1 2019 | $106,730,000 | +117.5% | 2,735,267 | +18.8% | 3.12% | +58.2% |
| Q4 2018 | $49,072,000 | -44.7% | 2,301,667 | +2.6% | 1.97% | -27.7% |
| Q3 2018 | $88,814,000 | +4.3% | 2,243,356 | +0.7% | 2.73% | -5.6% |
| Q2 2018 | $85,157,000 | +116.6% | 2,228,656 | +70.3% | 2.89% | +90.6% |
| Q1 2018 | $39,321,000 | +35.4% | 1,308,526 | +40.8% | 1.52% | +20.2% |
| Q4 2017 | $29,041,000 | -19.6% | 929,326 | -27.9% | 1.26% | -29.1% |
| Q3 2017 | $36,114,000 | +29.3% | 1,289,332 | -11.7% | 1.78% | +4.8% |
| Q2 2017 | $27,922,000 | +99.6% | 1,459,616 | +77.8% | 1.70% | +87.2% |
| Q1 2017 | $13,987,000 | -8.1% | 820,836 | -1.4% | 0.91% | -30.7% |
| Q4 2016 | $15,214,000 | +2.1% | 832,736 | -9.2% | 1.31% | +10.6% |
| Q3 2016 | $14,903,000 | – | 916,626 | – | 1.18% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 1,204,615 | $37,644,219,000 | 39.61% |
| Casdin Capital, LLC | 400,000 | $12,500,000 | 3.04% |
| Opaleye Management Inc. | 210,000 | $6,652,000 | 2.13% |
| Orbimed Advisors | 4,129,638 | $129,051,000 | 1.63% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 1,190,516 | $37,204,000 | 1.46% |
| Redmile Group, LLC | 929,326 | $29,041,000 | 1.26% |
| Cormorant Asset Management, LP | 337,876 | $10,559,000 | 1.10% |
| Perceptive Advisors | 781,309 | $24,416,000 | 0.81% |
| Rock Springs Capital Management LP | 525,000 | $16,406,000 | 0.74% |
| Virtus ETF Advisers LLC | 11,898 | $372,000 | 0.47% |